According to new research covered by io9, people with eating disorder histories are using GLP-one medications—drugs originally developed for diabetes and weight management—at alarming rates. GLP-one receptor agonists suppress appetite, a mechanism that may dangerously appeal to those with eating disorders. The research highlights a concerning trend: vulnerable populations are accessing these drugs outside standard medical oversight, with potential for serious harm to mental and physical health.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton